Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Sotorasib for previously treated KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer
Drug guidance

Sotorasib for previously treated KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer

Condition

Cancer

Respiratory

16 September 2025

-

Published on 16 Sep 2025
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended sotorasib for inclusion on the MOH List of Subsidised Drugs for previously treated Kirsten Rat Sarcoma glycine-to-cysteine at Codon 12 (KRAS G12C)-mutated locally advanced or metastatic non-small-cell lung cancer. The decision was based on lack of clinical- and cost-effectiveness of sotorasib compared with docetaxel, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for sotorasib are provided in the Annex.

Sotorasib for previously treated KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer (Published 16 Sep 2025) [PDF, 248 KB]

Sotorasib for previously treated KRAS G12C-mutated advanced non-small-cell lung cancer (Published 16 Sep 2025) [PDF, 90 KB]

Back to top